These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort. Canu E; Rugarli G; Coraglia F; Basaia S; Cecchetti G; Calloni SF; Vezzulli PQ; Spinelli EG; Santangelo R; Caso F; Falini A; Magnani G; Filippi M; Agosta F J Neurol; 2024 May; 271(5):2716-2729. PubMed ID: 38381175 [TBL] [Abstract][Full Text] [Related]
25. Amyloid-Tau-Neurodegeneration Profiles and Longitudinal Cognition in Sporadic Young-Onset Dementia. Vipin A; Koh CL; Wong BYX; Zailan FZ; Tan JY; Soo SA; Satish V; Kumar D; Wang BZ; Ng ASL; Chiew HJ; Ng KP; Kandiah N J Alzheimers Dis; 2022; 90(2):543-551. PubMed ID: 36155511 [TBL] [Abstract][Full Text] [Related]
26. The Impact of Amyloid-β or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease. Jang H; Kim HJ; Choe YS; Kim SJ; Park S; Kim Y; Kim KW; Lyoo CH; Cho H; Ryu YH; Choi JY; DeCarli C; Na DL; Seo SW; J Alzheimers Dis; 2020; 78(2):573-585. PubMed ID: 33016911 [TBL] [Abstract][Full Text] [Related]
27. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585 [TBL] [Abstract][Full Text] [Related]
28. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Slot RER; Verfaillie SCJ; Overbeek JM; Timmers T; Wesselman LMP; Teunissen CE; Dols A; Bouwman FH; Prins ND; Barkhof F; Lammertsma AA; Van Berckel BNM; Scheltens P; Sikkes SAM; Van der Flier WM Alzheimers Res Ther; 2018 Aug; 10(1):76. PubMed ID: 30081935 [TBL] [Abstract][Full Text] [Related]
29. Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. van de Beek M; Ooms FAH; Ebenau JL; Barkhof F; Scheltens P; Teunissen CE; van Harten AC; van der Flier WM; Lemstra AW Neurology; 2022 Mar; 98(12):e1262-e1272. PubMed ID: 35074893 [TBL] [Abstract][Full Text] [Related]
30. Sex differences in the association between AD biomarkers and cognitive decline. Koran MEI; Wagener M; Hohman TJ; Brain Imaging Behav; 2017 Feb; 11(1):205-213. PubMed ID: 26843008 [TBL] [Abstract][Full Text] [Related]
31. Synergistic interaction between amyloid and tau predicts the progression to dementia. Pascoal TA; Mathotaarachchi S; Shin M; Benedet AL; Mohades S; Wang S; Beaudry T; Kang MS; Soucy JP; Labbe A; Gauthier S; Rosa-Neto P; Alzheimers Dement; 2017 Jun; 13(6):644-653. PubMed ID: 28024995 [TBL] [Abstract][Full Text] [Related]
32. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition. Tan CH; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Dillon WP; Bonham LW; Yokoyama JS; Karch CM; Brewer JB; Rabinovici GD; Miller BL; Schellenberg GD; Kauppi K; Feldman HA; Holland D; McEvoy LK; Hyman BT; Bennett DA; Andreassen OA; Dale AM; Desikan RS; Acta Neuropathol; 2018 Jan; 135(1):85-93. PubMed ID: 29177679 [TBL] [Abstract][Full Text] [Related]
33. Tau PET in Alzheimer disease and mild cognitive impairment. Cho H; Choi JY; Hwang MS; Lee JH; Kim YJ; Lee HM; Lyoo CH; Ryu YH; Lee MS Neurology; 2016 Jul; 87(4):375-83. PubMed ID: 27358341 [TBL] [Abstract][Full Text] [Related]
34. Visual Rating of Posterior Atrophy as a Marker of Progression to Dementia in Mild Cognitive Impairment Patients. Kim HR; Park YH; Jang JW; Park SY; Wang MJ; Baek MJ; Kim BJ; Ahn S; Kim S J Alzheimers Dis; 2017; 55(1):137-146. PubMed ID: 27636842 [TBL] [Abstract][Full Text] [Related]
36. Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease. Myers PS; O'Donnell JL; Jackson JJ; Lessov-Schlaggar CN; Miller RL; Foster ER; Cruchaga C; Benitez BA; Kotzbauer PT; Perlmutter JS; Campbell MC Neurology; 2022 Jul; 99(1):e66-e76. PubMed ID: 35418463 [TBL] [Abstract][Full Text] [Related]
37. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
38. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. Ebenau JL; Pelkmans W; Verberk IMW; Verfaillie SCJ; van den Bosch KA; van Leeuwenstijn M; Collij LE; Scheltens P; Prins ND; Barkhof F; van Berckel BNM; Teunissen CE; van der Flier WM Neurology; 2022 Mar; 98(13):e1315-e1326. PubMed ID: 35110378 [TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210 [TBL] [Abstract][Full Text] [Related]
40. Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. van der Kall LM; Truong T; Burnham SC; Doré V; Mulligan RS; Bozinovski S; Lamb F; Bourgeat P; Fripp J; Schultz S; Lim YY; Laws SM; Ames D; Fowler C; Rainey-Smith SR; Martins RN; Salvado O; Robertson J; Maruff P; Masters CL; Villemagne VL; Rowe CC Neurology; 2021 Feb; 96(5):e662-e670. PubMed ID: 33184233 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]